![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 24, 2026
This phase 3 clinical trial is comparing aromatase inhibitors and ribociclib, with and without chemotherapy, to prevent recurrence
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
April 24, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
March 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for adults aged 75+ with early-stage melanoma
March 30, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
March 30, 2026
These studies aim to improve patient outcomes and well-being by examining complex interactions between patients, providers, and care delivery systems
March 30, 2026
The latest findings in breast cancer, cancer care delivery research, head and neck cancer, leukemia, and radiation therapy
March 30, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning
February 27, 2026
Liquid biopsies are now permitted for eligibility determination, while trial participants may use progression biopsies to explore treatment options
February 27, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent